Full Text View
Tabular View
No Study Results Posted
Related Studies
DAHANCA 19: The Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
This study is currently recruiting participants.
Study NCT00496652   Information provided by Danish Head and Neck Cancer Group
First Received: July 3, 2007   Last Updated: December 20, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer of the Head and Neck
Additional conditions recognized in this trial
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
Radiotherapy
Zalutumumab
Sponsors listed in this trial
Danish Head and Neck Cancer Group


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services